Mercy South - David M Sindelar Cancer Center ( Site 0098) — St Louis, Missouri

Mercy South - David M Sindelar Cancer Center ( Site 0098) is a clinical research site located in St Louis, Missouri, United States 63128.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Mercy South - David M Sindelar Cancer Center ( Site 0098) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Non Small Cell Lung Cancer.

Sponsors: Merck Sharp & Dohme LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in St Louis

Browse all research sites in Missouri · View every site in St Louis

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Mercy South - David M Sindelar Cancer Center ( Site 0098)?

Mercy South - David M Sindelar Cancer Center ( Site 0098) has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Mercy South - David M Sindelar Cancer Center ( Site 0098) conducted?

Mercy South - David M Sindelar Cancer Center ( Site 0098) has 1 clinical trials on record, with 1 currently active. Their work covers Non Small Cell Lung Cancer.

Is Mercy South - David M Sindelar Cancer Center ( Site 0098) accredited by Crixeo Clinical Trials?

Mercy South - David M Sindelar Cancer Center ( Site 0098) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Mercy South - David M Sindelar Cancer Center ( Site 0098)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.